FDA仿制药办公室:美国九成处方为仿制药,通过严格审评保障可及性
Generic Drugs
美国每10张处方中有9张为仿制药。FDA药品评价与研究中心下属仿制药办公室(OGD)通过管理审评流程促进药品批准、开展仿制药科学研究、发布研发与审评数据报告并提供教育资料,以保障美国公众获得高质量、可负担的仿制药。FDA仅在审查证明药品获益大于风险的广泛检测数据后才予以批准。
In the United States, 9 out of 10 prescriptions filled are for generic drugs. Increasing the availability of generic drugs helps to create competition in the marketplace, which then helps to make treatment more affordable and increases access to healthcare for more patients. Learn more about the FDA Drug Competition Action Plan.
The FDA's Office of Generic Drugs (OGD) within the Center for Drug Evaluation and Research ensures high-quality, affordable generic drugs are available to the American public by following a rigorous review process that includes:
- Managing the regulatory process to facilitate drug approvals,
- Establishing science initiatives to research generic drugs,
- Publishing data and reports on generic drug development and review, and
- Offering educational materials and information.
Approval Process
FDA approves a drug only after reviewing extensive testing showing that a drug will provide the benefits described in its labeling, and that those outweigh its risks.
Science & Research
FDA generic drug regulatory science initiatives, research priorities and reports, public workshops, and opportunities for collaboration
Complex Generics News
Generally, complex generics have complex active ingredients, formulations, dosage forms, or routes of administration, or are complex drug-device combination products.
FDA Consumer Updates
Science-based health and safety information you can trust on all FDA-approved products.
Contact Us
- Office of Drug Information
- Email: druginfo@fda.hhs.gov
- Telephone: 855-543-3784
- MedWatch: The FDA Safety Information and Adverse Event Reporting Program
来源:FDA 官方药品与生物制品信息 · fda.gov